GenomiCare is proud to announce that it has won the 2020 Leading Sci-Tech Innovation Company Award for its innovations in the R&D of cancer precision medicine and that Dr. Xu Qiang, the company’s founder and CEO, has been named a 2020 Sci-Tech Innovation Leader. The awards were announced on December 22, 2020 at the 2020 International Sci-Tech Innovation Festival & Global Digital Conference (ISTF & GDC) organized by syobserve.com in collaboration with leading Chinese media in sci-tech, business and finance news, including China Daily and 36Kr.
The ISTF & GDC is a diversified platform for engagement, open communication and cooperation. With the goal of helping advance China’s technological strength, it promotes the momentum of sci-tech innovation and focuses on the latest sci-tech trends as well as emerging technologies and application cases across the world. The annual “Leading Lights of Sci-Tech Innovation” list highlights trailblazing companies and professionals in China’s sci-tech innovation community. Paying tribute to their extraordinary achievements and capabilities, these awards encourage more Chinese companies to contribute to the high-quality development of the country’s economy.
As a company specialized in cancer precision medicine and oncology drug development and commercialization, GenomiCare is honored to join other leading R&D-powered enterprises like iFLYTEK, Siemens Healthineers, Takeda, Didi Chuxing and Haier Group in receiving this recognition.
Since established in 2015, GenomiCare has been providing data-driven drug development services to biopharma and pharmaceutical companies globally as a powerful and flexible platform for oncology drug development and commercialization.
GenomiCare developed a proprietary system named Clinical Intelligence Analysis Platform (CIAP) that integrates clinical-genomic Real World Evidence (RWE) knowledgebase and comphrehensive genomic data (WES). Anchored as reverse transtational frontier, GenomiCare’s data-driven algorithm provides a solution to optimize the clinical hypothesis by combining “Deep clinical + Deep Genomic” knowledgebase, with or without prior treatment-specific clinical trial data. It can help in indication expansion, clinical trial design and verification for oncology drug development and commercialization.
The comphrehensive longitudinal clinical data represents the complexity and diversity of real-world diagnosis and treatment, also in combined with comprehensive genomics data, provides a powerful panorama of Chinese real-world oncology treatment journey for new drug development. Through the application of NLP Machine Learning, comprehensive data mining can be achieved under the scope with or without additional datasets (such as public scientific research databases, clinical trial data sets, etc.), Genomicare is a able to help pharma achieve biomarkers indentification, indication expansion and new target development.
As the future trend of drug development, innovation presents enormous challenges to drug companies. Fortunately, the toolset of “data + intelligence” is ready to generate more opportunities for them. GenomiCare and other emerging drug developers will leverage medical data and intelligent technologies to push ahead oncology drug development more efficiently and benefit patients in China and beyond.